Rapid Diagnostic Testing for Response to the Monkeypox Outbreak — Laboratory Response Network, United States, May 17–June 30, 2022
Monkeypox
Orthopoxvirus
Biodefense
Variola virus
DOI:
10.15585/mmwr.mm7128e1
Publication Date:
2022-07-08T14:44:35Z
AUTHORS (77)
ABSTRACT
As part of public health preparedness for infectious disease threats, CDC collaborates with other U.S. officials to ensure that the Laboratory Response Network (LRN) has diagnostic tools detect Orthopoxviruses, genus includes Variola virus, causative agent smallpox. LRN is a network state and local health, federal, Department Defense (DOD), veterinary, food, environmental testing laboratories. developed, Food Drug Administration (FDA) granted 510(k) clearance* Non-variola Orthopoxvirus Real-time PCR Primer Probe Set (non-variola [NVO] assay), polymerase chain reaction (PCR) test NVO. On May 17, 2022, was contacted by Massachusetts Public Health (DPH) regarding suspected case monkeypox, caused Monkeypox virus. Specimens were collected tested DPH laboratory capability using NVO assay. Nationwide, 68 laboratories had capacity approximately 8,000 tests per week during June. During 17-June 30, 2,009 specimens from monkeypox cases. Among those, 730 (36.3%) 395 patients positive NVO-positive 159 persons confirmed be monkeypox; final characterization pending 236. Prompt identification infection allowed rapid response outbreak, including isolation treatment patients, administration vaccines, action. To further facilitate access increase convenience providers existing provider-laboratory relationships, are supporting five large commercial national footprint (Aegis Science, LabCorp, Mayo Clinic Laboratories, Quest Diagnostics, Sonic Healthcare) establish 10,000 laboratory. July 6, first began accepting based on clinician orders.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (6)
CITATIONS (55)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....